BlossomHill Therapeutics, Inc.
BLSM
Get informed when a big investor buys or sells
+ FollowMarket Cap$508.34M
Close$
$3.93
77.2% downside
Current Fair Value
77.2% downsideOvervalued by 77.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $508.34 Million |
|---|---|
| Enterprise Value | $436.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.08 |
| Beta | 0 |
| Outstanding Shares | 27,136,960 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.85 |
|---|---|
| PEG | -1.46 |
| Price to Sales | - |
| Price to Book Ratio | 5.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.93
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BlossomHill Therapeutics, Inc.
69 employees
CEO: Jing Rong Jean Cui Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.